Current Clinical Trials

Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Golden Biotech
Details (Identifier #): NCT02047344
Title: GHNSCLC-2-001, A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients with Stage IV (including Pleural Effusion) Non-Squamous Non-Small Cell Lung Cancer (NSCLC) who have Failed Two Lines of Anti-Cancer Therapy
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02585713
Title: RU221501I, A Phase III, Randomized, Open label Study Evaluating the Safety of Apixaban in Subjects with Cancer Related Venous Thromboembolism (BMS# CV185-444)
Department: Surgery
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Sadik MD, Karim
Sponsor: Internal FDN
Details (Identifier #): NCT02250924
Title: Prospective, Randomized caffeinated Gum to Prevent Post-Operative Ileus: A , Placebo-controlled trial
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Sporn M.D., Daniel
Sponsor: Janssen
Details (Identifier #): NCT01877915
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure COMMANDER HF Study
Department: Cardiology
Diagnosis: Cardiac - Surgery
Principal Investigator: Sporn M.D., Daniel
Sponsor: Abbott VD
Details (Identifier #): n/a
Title: GRAFTMASTER® RX Coronary Stent Graft System(JOSTENT)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Details (Identifier #): NCT01674140
Title: S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer